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Abstract
Background: Childhood-onset spondyloarthropathies usually start with enthesitis and peripheral arthritis. However,
axial disease may develop afterward. Patients are most often classified, following revised (Edmonton 2011) ILAR criteria,
as enthesitis-related arthritis, psoriatic arthritis, or unclassified juvenile idiopathic arthritis, particularly in cases of psoriasis
in the patient or a first-degree relative. In adults, peripheral spondyloarthritis is classified by ASAS criteria.
Methods: We retrospectively studied patients with childhood-onset spondyloarthropathies followed for more than
one year in our referral centre. We did not exclude patients with a personal or familial history of psoriasis.
Results: We included 114 patients followed between January 2008 and December 2015 for a median of 2.5 years
(IQR = 2.3). Sixty-nine per-cent of patients fulfilled the revised ILAR classification criteria for enthesitis-related arthritis,
and 92% the ASAS criteria for peripheral spondyolarthritis (p < 0.001). Axial disease and sacroiliitis were rare at disease
onset. However, they appeared during follow-up in 63% and 47% of cases respectively, after a median disease duration
of 2.6 (IC 95% [2.2–4.4]) and 5.3 years (IC 95% [4.1–7.7]), respectively. Multivariable analysis showed that familial history
of spondyloarthritis was associated with the presence of sacroiliitis and active disease at the latest follow-up (OR = 3.61
[1.5–8.7], p < 0.01 and 2.98 [1.2–7.3], p = 0.02, respectively).
Conclusion: Axial involvement developed in most patients within five years. Revised Edmonton criteria were less
sensitive than ASAS criteria to classify patients as having childhood-onset spondyloarthropathies. The main risk factor
for both sacroiliitis and persistent active disease was a familial history of spondyloarthritis.
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Background
Juvenile idiopathic arthritis (JIA) is a heterogeneous
group of inflammatory joint diseases of unknown aeti-
ology, defined by the presence of chronic arthritis before
the age of 16 years. It is the most common disease
treated in paediatric rheumatology clinics with a preva-
lence of 16 to 150/100,000 children [1]. Each form of
JIA is defined by specific and non specific clinical char-
acteristics [2]. The last published classification criteria
for JIA are the 2002 Edmonton criteria [2]. Enthesitis-
related arthritis (ERA), one JIA subcategory, and psori-
atic arthritis (PsA) comprise most cases of paediatric
spondyloarthritis (SpA) (Additional file 1: Table S1).
ERA represents up to 20% of JIA cases and usually starts
after six years of age [1, 3]. The principle of the Edmon-
ton classification is that all categories of JIA are mutually
exclusive, which is reflected by the presence of the un-
defined juvenile arthritis category. Patients with juvenile
SpA (JSpA), who do not fulfil either the ERA or PsA cri-
teria are classified in this last category [2].
SpA is a heterogeneous group of inflammatory diseases,
first identified in adults. It is characterised by a strong
association with HLA-B27 [4]. The disease spectrum is
large, ranging from reactive arthritis to ankylosing spon-
dylitis (AS). SpA is defined by a high risk of axial disease,
typically with sacroiliitis. Some patients present extra-
articular disease, such as uveitis or psoriasis. The paediat-
ric form differs from that of adults by a more peripheral
pattern of arthritis with less frequent axial disease, at least
at disease onset. Evolution to ankylosis is reported in one
third of cases after several years of disease [5]. The re-
ported frequency of ankylosis varies greatly, depending on
the study, in 9% to 75% of cases [6]. Little is known about
the long-term outcome of JSpA. The remission rate is re-
ported to be between 17% and 37%, with a severe handi-
cap in 4% to 52% of cases [6]. Few studies have compared
adult to juvenile SpA. One study showed a worse outcome
with more disability for JSpA [7].
In adults, the first set of criteria identified only late stage
axial SpA, with defined X-ray sacroiliitis (New York cri-
teria) [4]. Various criteria have been progressively pro-
posed to classify the disease at an earlier stage. Until
recently, most criteria mainly focused on axial disease
with little interest in peripheral disease. Recently the As-
sessment of Spondylarthritis International Society (ASAS)
published two classification criteria sets, one for axial
forms in 2009 [8] and one for peripheral forms in 2011
[9]. Peripheral criteria are: the presence of arthritis, dacty-
litis, or enthesitis, associated with at least one major criter-
ion (uveitis, psoriasis, inflammatory bowel disease,
infectious trigger, presence of HLA-B27, or sacroiliitis) or
at least two minor criteria (arthritis, enthesitis, dactylitis,
inflammatory back pain, or a familial history of SpA) [9].
In children, the situation is more complex, with some
studies using adult and others paediatric criteria, mainly
the revised Edmonton criteria for JIA. However paediatric
cases of SpA do not always fulfil the Edmonton criteria of
ERA: some are classified as PsA or undifferentiated JIA.
The lack of diagnostic consensus, with multiple classifica-
tion criteria, is a limiting factor for meta-analyses [4, 10].
We performed a retrospective study of all JSpA patients
followed in a paediatric rheumatology tertiary care centre
at Necker Hospital in Paris to determine the initial presen-
tation and outcome of patients, including response to
treatment, and analyse the risk factors for axial disease or
active disease at the last follow up. In addition, we ana-
lysed the proportion of patients diagnosed as ERA or SpA
according to the revised Edmonton classification criteria
and the latest ASAS criteria, respectively.
Methods
Patients
In this retrospective study, we enrolled all patients evalu-
ated at a French national reference centre for juvenile
arthritis in Necker-Enfants Malades hospital and the
paediatric rheumatology outpatient clinic of Saint-
Vincent-de-Paul Hospital between January 2008 and De-
cember 2015. Patients were recruited through the “Centre
de Référence des Maladies Rares (CEMARA)” database
project [11]. The recording of patient, parent information,
data collection and analysis were conducted in accordance
with French national guidelines. CEMARA has been au-
thorized by the French National Committee on Informat-
ics and Liberty. According to French legislation, patients
and parents were informed, but informed consent was not
required for a retrospective analysis.
The inclusion criteria were having ERA or JSpA, with
disease onset at an age of less than 16 years, diagnosed
by the attending physician, and confirmed at the latest
follow-up visit. We did not exclude patients with a per-
sonal or familial history of psoriasis. Patients followed
for less than one-year or primarily diagnosed with in-
flammatory bowel disease were excluded.
Data collection
For each patient, we collected information concerning
gender, age at disease onset, age at first visit, personal
and familial history of inflammatory and auto-immune
disease and psoriasis, presence of the HLA-B27 allele,
description of the clinical course, date of first axial in-
volvement, and biological and radiological tests from the
medical chart. Data collection was performed two times
by one investigator, first from the computerized medical
chart and then from the paper chart. We also analysed
the response to various treatments and adverse events.
We noted any history of uveitis, psoriasis, or IBD to
highlight extra-articular manifestation. Imaging data
were recorded and analysed as described below.
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Clinical and radiological assessment
We defined axial disease by the presence of at least one
criterion among: 1) inflammatory low-back pain or inflam-
matory dorsal pain lasting more than one month; 2) limited
spine mobility, defined by a Schober index < 10 + 4 cm; 3)
sacroiliac pain at examination or alternating buttock pain;
or 4) presence of axial disease by any available radiological
examination. Active sacroiliitis was defined as sacroiliac
pain at examination, alternating buttock pain or the pres-
ence of an active lesion by MRI. A joint was considered to
be active if at least two criteria among inflammatory pain,
limited mobility, and/or swelling were present. Enthesitis
was defined as chronic inflammatory pain or tenderness at
the site of principal tendon insertion: plantar fascia inser-
tion at the metatarsal heads and calcaneum, Achilles ten-
don insertion at the calcaneum, quadriceps insertion at the
patella and proximal tibia, pelvis (anterior superior iliac
spine, iliac crest), and greater trochanter.
An experienced pediatric radiologist (SB) reviewed all
available sacroiliac MRI, assessing the presence of acute
lesions (synovitis or articular effusion, bone oedema, or
enthesitis) and chronic lesions (bone erosion, bone
sclerosis, degenerative fatty infiltration of the bone, or
ankylosis). Active sacroiliitis by MRI was defined by the
presence of at least one acute lesion. Our expert radiolo-
gist did not systematically review other radiological
examinations, such as CT-scans scan or standard radiog-
raphy. Interrater reliability of MRI evaluations was mea-
sured with kappa coefficients. A result of k < 0.40
indicated poor agreement, 0.40–0.59 fair agreement,
0.60–0.74 moderate agreement, and 0.75–1.00 excellent
agreement [12].
Assessment of response to treatment
Clinical response to treatment was evaluated based on
the information recorded from the medical chart: reduc-
tion of arthritis and clinical symptoms for at least six
months, when available, and the treating physician
evaluation. Inactive disease was defined as the absence
of arthritis and enthesitis during clinical examination.
Clinical remission was defined as the absence of symp-
toms, noted by the treating rheumatologist, for at least
six months, with or without treatment.
Prognostic factors
We analysed the following variables; masculine gender,
presence of HLA-B27, age of first symptoms under
12 years, hip arthritis, presence of enthesitis, and family
history of SpA.
Statistical analysis
All statistical analyses were performed with R (version
3.2.2). Comparisons between patient groups were per-
formed using the chi-squared test and Fisher’s exact test
for qualitative variables, and Student’s t-test for quantita-
tive variables. Survival analyses were performed using
the Kaplan Meier method. Multivariable analysis, using a
logistic model, was performed to determine variables, in-
cluding disease severity indicators. The predictors used
in the final model were those showing a significant cor-
relation (p ≤ 0.05) with sacroiliac (SI) involvement in the
univariate analysis.
Results
Baseline characteristics
Between January 2008 and December 2015, 373 patients
were seen in our centre for a suspicion of ERA or JSpA.
We excluded 34 patients with other diagnoses and 225
followed for less than one year, because they were mainly
seen for a second opinion from our National reference
centre and then included in the CEMARA database but
followed afterwards in their regional centre. We included
114 patients (Fig. 1). The median follow up was 2.6 years
(1.0 to 7.2 years). The baseline characteristics are pre-
sented in Table 1.
At the beginning of follow-up, only 53 patients (46%)
of our population were classified in the ERA group, ac-
cording to the Edmonton classification criteria, with a
significant difference between boys and girls (57% versus
29%, respectively, p < 0.01) and two patients (1.75%) in
the PsA. According to the 2011 ASAS criteria, 83,pa-
tients (73%) could be classified with peripheral SpA at
the first consultation, with no difference between gen-
ders (Table 2).
Fig. 1 Flow chart. CEMARA, a French information system for rare
disease. ERA, Enthesitis-related arthritis. JSpA,
juvenile Spondyloarthritis
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Cumulative symptoms at the last follow up
During follow-up, 99 patients (87%) developed periph-
eral arthritis (Table 3), predominantly of the lower limbs
(knee: 58%; hips: 46%, ankle: 38%). Table 3 presents the
frequency of involvement for each joint. Enthesitis was
recorded in 98 medical reports (86%) mostly in the
lower limbs (Table 3): Achilles tendon or plantar fascia
attachment to the calcaneus for 84 patients (74%), quad-
ricipital tendon attachment to the knee for 53 patients
(46%), and plantar fascia attachment to the metatarsal
head for 45 patients (39%).
Axial disease was active at the latest follow-up in 72
patients (63%). Fifty-four patients (47%) developed
sacroiliitis (Table 3). The median disease duration before
the onset of axial symptoms or sacroiliitis was 2.6 years
(IC95 = [2.2–4.4], Fig. 2a) and 5.3 years (IC95 = [4.1–7.7],
Fig. 2b), respectively. After five years of evolution,
Kaplan-Meier estimates showed that axial disease and
sacroiliitis would be present in 66% (IC95 = [54.1–74.6];
Fig. 2) and 48.4% of cases (IC95 = [44.6–58.2]), respect-
ively. Inflammatory back pain showed the same pattern
(Additional file 2: Figure S1). There was no difference
between boys and girls (p = 0.98).
Thirty-seven of 73 patients with inflammatory back pain
(IBP) or sacroiliac tenderness (51%) underwent MRI
examination. Axial involvement was confirmed for 18 pa-
tients (13/24 boys and 5/13 girls). There were 28 sacroiliac
MRI for 21 patients available for review by our expert
radiologist. For nine patients, the MRI were not copied on
our imaging server and no CD was available for review.
Our radiologist disagreed with the initial MRI interpret-
ation for five cases (sacroiliitis had been undiagnosed in
one case and overstated in four). The interrater reliability
was fair as evaluated by the kappa statistic (k = 0.49, IC95
= [0.12–0.86]). Sacroiliitis was confirmed for five patients,
based on acute lesions in all five and chronic lesions in
two. Acute lesions consisted of synovitis and articular ef-
fusion in five cases and bone oedema in four. Chronic le-
sions consisted of erosion and sclerosis in two cases and
degenerative fatty infiltration in one.
At the last follow-up, after a median disease duration
of 4.3 years (1.3 to 11.2), 105 patients (92%) met the
2011 ASAS criteria for peripheral SpA, with no differ-
ence between genders. Seventy-nine patients (69%) met
the Edmonton criteria for ERA and six (5.3%) those for
PsA, together identifying 74.3% of the patients as having
SpA, witch is significantly less than the ASAS criteria
for peripheral SpA.
Response to treatment and tolerance
Clinical improvement and clinical remission were
recorded for 96 (84.2%) and 52 patients (45.6%),
respectively, treated solely with NSAIDs. Polyarthritis
during the first years of the disease or axial involve-
ment were predictive of non-response to NSAID ther-
apy (OR = 0.31, p = 0.06 and OR = 0.24, p = 0.05,
respectively). The most frequent adverse effect of
NSAIDs was gastralgia in 35% of cases. One serious
adverse event was documented (transient acute kidney
injury during viral gastroenteritis).
Table 1 Baseline characteristics
Total, n = 114
Sex ratio (boys/girls) 1.7
Age at 1st symptoms, median (IQR) 9.55 (2.7)
Disease duration at the 1st visit, median (IQR) 1.2* (2)
HLA-B27 49 (43%)
Familial history of SPA 1er degree 32 (28%)
Familial history of psoriasis 1er degree 17 (15%)
Familial history of inflammatory bowel disease 12 (10%)
Axial involvement 40 (35%)
Inflammatory back pain 23 (20%)
Sacroiliitis 33 (29%)
Peripheral arthritis 44** (2%)
Oligo-articular involvement 30 (56%)
Poly-articular involvement 14 (26%)
Enthesitis 39 (72%)
CI confidence interval, SpA Spondylarthritis, IQR interquartile range
Axial involvement was defined as 1) inflammatory low-back pain or
inflammatory dorsal pain lasting for more than one month; 2) limited
spine mobility, defined by a Schober index < 10 + 4 cm; 3), sacroiliac
pain at examination or alternating buttock pain; or 4) presence of axial
disease by imagery. Sacroiliitis was defined as 1) sacroiliac pain at examination
or alternating buttock pain; or 2) presence of sacroiliitis by either MRI or
standard radiography
* There was a significant difference between boys and girls (1.5 years vs.
2.3 years respectively, p = 0.04)
** Peripheral arthritis was more frequent in boys than girls (87 vs. 67%
respectively, p = 0.03)
Table 2 Comparison between ASAS criteria for peripheral
spondyloarthritis and current revised ILAR classification criteria
for ERA
ASAS criteria
for peripheral
SpA
ILAR criteria
for ERA
or PsA
p
1st consultation (%)
All patients 83 (73%) 55 (48%) < 0.01
Boys 55 (76%) 43 (60%) 0.03
Girls 28 (67%) 12 (29%) < 0.01
Last follow up (%)
All patients 105 (92%) 85 (75%) < 0.01
Boys 65 (90%) 56 (78%) 0.04
Girls 40 (95%) 32 (76%) 0.01
ASAS Assessment of Spondyloarthritis International Society, ILAR International
League of Association for Rheumatology, ERA enthesitis related arthritis
In our cohort, the ASAS criteria more efficiently diagnosed juvenile
spondyloarthritis than the ILAR criteria. Furthermore, the ILAR criteria
performed more poorly in the diagnosis of the disease during the first year in
girls than boys (p = 0.001)
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Anti-TNF therapy was given to 48 patients (42.1%)
after a median disease duration of 5.4 years (IC95 = [4.6–
8.0], Additional file 3: Figure S2A) Thirty-three patients
(69%) presented axial disease before instauration of the
first biotherapy, with a median axial disease duration of
0.6 years. All patients received NSAIDs before the intro-
duction of anti-TNF. A second anti-TNF agent was ad-
ministered to 13 patients. Anti-TNF treatment resulted
in inactive disease for 58.3% of cases after six months
(IC95 = [42.7–69.6]) and 68.6% after one year (IC95
= [52.0–79.5], Additional file 3: Figure S2B), with no dif-
ferences between etanercept and adalimumab (p > 0.5).
Boys had a better response than girls to both anti-TNF
therapies (OR = 6.94, p < 0.01). Treatment tolerance was
good. The most frequent adverse events were allergic re-
actions (five patients). One patient developed an inflam-
matory bowel disease after the initiation of etanercept.
Another had to stop treatment because of recurrent
infection.
At the latest follow-up, 63 patients (55%) were in clin-
ical remission, including 23 (20%) off therapy.
Prognostic factors
The only prognostic factor associated in univariate ana-
lysis with both active disease at the last follow-up and
sacroiliitis was a familial history of SpA (OR = 3.1, p = 0.01
and OR = 3.6, p < 0.01, respectively; Table 4). This result
was confirmed in multivariable analysis (OR = 3.6, p
< 0.01 and OR = 3.1, p = 0.01, respectively). Enthesitis was
associated with sacroiliitis (OR = 4.2, p = 0.04 in multivari-
able analysis). Male gender was the only prognostic factor
associated with a lower risk of active disease at last follow
up (OR = 0.3, p = 0.01) in univariate, but not multivariable
analyses (OR = 0.4, p = 0.06). We did not find any other
prognostic factor (Table 4).
Discussion
This study describes the initial clinical presentation and
natural history of a large cohort of patients diagnosed
with JSpA/ERA and followed in a tertiary care paediatric
rheumatology centre. There was progressive occurrence
of axial disease in two-thirds of cases. Initial treatment
consisted of NSAIDs and resulted in inactive disease in
45.6% of cases. Half of the patients received anti-TNF
therapy several years after disease onset and two-thirds
achieved inactive disease within one year. A family his-
tory of SpA was the main risk factor for axial disease,
sacroiliitis and persistently active disease at the last
follow-up. This study is based on one of the largest
paediatric SpA cohorts yet published.
There was an association of male gender (Sex ratio =
1.7) and HLA-B27 (56%) with JSpA, in accordance with
the literature [3, 13, 14]. The median age at disease on-
set (9.5 years) was similar to that reported in the litera-
ture [6, 15–19].
Our study confirmed a low rate of symptomatic axial
disease at disease onset, with a marked increase, how-
ever, within the first years of the disease: 60% of our pa-
tients showed axial involvement after five years. This
was also true when studying only sacroiliitis or inflam-
matory lumbar pain. Axial disease has generally been
considered to be rare in JSpA since it and sero-negative
forms were first described [20–22]. In contrast to the
adult form, in which inflammatory back pain is often a
major symptom at disease onset, axial involvement pro-
gressively appears months to years after the onset of
JSpA [3, 22–24]. Our study showed such progressive ap-
parition in a high proportion of patients, consistent with
the recent review by R. Burgos Vargas on adult onset un-
differentiated SpA and JSpA [23]. A similar progressive
increase of the incidence of defined ankylosing SpA has
been reported in cohorts of adult undifferentiated SpA
and JSpA, with the proportion of affected patients
Table 3 Cumulative symptoms from the first to last follow up
Total,
n = 114
Peripheral arthritis 99 (87%)
Oligo-articular involvement 66 (58%)
Hips 52 (46%)
Knee 66 (58%)
Ankle 43 (38%)
Mild-foot 10 (9%)
Metatarsophalangeal 19 (17%)
Shoulder 14 (12%)
Elbow 14 (12%)
Wrists 28 (25%)
Metacarpo-phalangian 15 (13%)
Proximal Interphalangial 14 (12%)
Dactylitis 15* (13%)
Enthesis 98 (86%)
Pelvic and greater trochanter
enthesitis
25 (22%)
Knee 53 (46%)
Plantar fascia insertion into
the metatarsal head
45 (39%)
Achilles’ tendon and fascia
plantar insertion into the calcaneus
84 (74%)
Axial involvement 72 (63%)
Dorsal spine 27 (24%)
Lumbar spine 50 (44%)
Sacroiliac joints 54 (47%)
We followed our cohort for a median duration of 2.6 years (IQR = 2.3) and the
median disease duration was 4.3 years (IQR = 3.2)
* Dactylitis was more frequent in girls than boys (26 vs. 6%,
respectively, p < 0.01)
Goirand et al. Pediatric Rheumatology  (2018) 16:21 Page 5 of 9
ranging from 12% to 42% after three to five years and
19% to 90% after nine to eleven years [23].
MRI results were available for 37 patients in our study
and confirmed axial disease in half, calling into question
the sensitivity and specificity of clinical examination to
determine axial involvement. In one study, the sensitivity
of physical examination was 23% and the specificity
67.9% [25]. The lack of specificity of clinical assessment
of axial symptoms is probably explained by the difficult
differential diagnosis with other painful conditions, such
as fibromyalgia, which may coexist in adults with SpA
[26, 27]. To our knowledge, there has been no studies on
the frequency of association between chronic pain syn-
dromes, such as fibromyalgia and any type of JIA. Al-
though MRI is a valuable tool to support axial
involvement, its interpretation by non-experienced radi-
ologists may be misleading in some cases, particularly in
children, as suggested here by the only fair rate of agree-
ment between the first radiologist and our expert radiolo-
gist who reviewed images and the low agreement
between radiologists in describing acute sacroiliac lesions.
Interpretation of sacroiliac MRI is challenging in children
and adolescents due to the presence of thick cartilaginous
growth plates which may be falsely interpreted as sacroi-
liitis [28]. Contrast injection may be particularly useful in
such cases to show evidence, or not, of inflammation, un-
like in adults in which it provides no added value over
STIR sequences in MRI of the sacroiliac joints in the
early detection of SpA [28].
The high response rates to NSAID therapy was con-
sistent with that reported for adult SpA. Anti-TNF,
mainly etanercept and adalimumab, were the only bio-
logical drugs used in our cohort. Most patients treated
with TNF antagonists responded rapidly, resulting in in-
active disease within 6 to 12 months, as also observed in
retrospective studies [25] and clinical trials of etanercept
[29, 30] and adalimumab for ERA or juvenile ankylosing
SpA [31, 32]. Etanercept fulfilled the PedACR 70 re-
sponse criteria for more than 55% of cases in the BIKER
prospective cohort [33]. The proportion of our patients
who achieved clinical remission was consistent with
those reported in the literature, with long-term follow-
up studies in adults showing remission rates between 17
and 44% [6].
Among several risk factors reported for adult SpA, a
familial history of SpA was the only risk factor
a
b
Fig. 2 Evolution of axial disease prevalence. a Axial involvement (defined as: 1) inflammatory low back pain or inflammatory dorsal pain lasting
for more than one month; 2) limited spine mobility; 3) sacroiliac pain at examination or intermittent buttock pain; or 4) presence of axial disease
by imagery.). b Sacroiliitis Axial involvement was rare in the first years of the disease with a progressive linear increase in its prevalence up to 60
to 70% after five years
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associated with both axial disease and sacroiliitis during
follow-up, whereas the presence of enthesitis was a risk
factor for sacroiliitis. Oligo-articular disease at first con-
sultation was a negative predictor of axial disease and
sacroiliitis. Published studies on JSpA contain discrepan-
cies regarding the risks due to male gender, age, family
history, hip arthritis, or articular counts [15, 34, 35].
One of the major difficulties to summarize these data is
the absence of a consensus concerning the way to diag-
nose axial disease, some using clinical criteria, others
conventional imaging techniques or MRI.
Here both univariate and multivariable analyses also
showed a familial history of SpA to be the sole risk factor of
active disease at the last follow-up after a median disease
duration of 4.3 years. Only one study previously analysed risk
factors associated with failure to achieve clinical remission: in
2006, B. Flatø et al. showed that female gender, a family his-
tory of ankylosis SpA in a first degree-relative, and ankle
arthritis within the first six months were associated with fail-
ure to achieve remission after 15 years of follow-up [6].
Our study also assessed the 2011 ASAS criteria for per-
ipheral SpA in a paediatric population, showing them to be
much more sensitive than the Edmonton classification cri-
teria for ERA, even when associated with the psoriasis JIA
criteria. This may be due to several factors. First, the
principle of the Edmonton criteria is that all categories are
mutually exclusive. Patients who cannot be classified in any
of the six types of JIA (oligo arthritis, polyarthritis
rheumatoid factor negative, polyarthritis rheumatoid factor
positive, ERA, PsA, or systemic arthritis) are classified as
having undefined JIA. In the case of SpA, the fact that PsA
is separated from other types of SpA classified in the ERA
group is problematic. As discussed in the literature [36],
some patients with a typical clinical picture of SpA, but
with a familial history of psoriasis, are excluded from the
ERA group and are classified as having undefined arthritis.
On the other hand, male patients with HLA-B27 and older
than six years at first symptoms are excluded from the PsA
group in the Edmonton criteria. The place of psoriasis
should be reconsidered in future classifications [37]. Sec-
ond, ERA criteria had a lower sensitivity in girls than boys
in our study, possibly may due to the fact that one ERA cri-
terion is male gender and age over six at disease onset,
leading girls with peripheral arthritis in adolescence to be
mainly classified as undifferentiated JIA. The good sensitiv-
ity of ASAS criteria for peripheral SpA in our cohort, as in
a previous study [38], supports the view by R. Burgos Var-
gas [23] that the ASAS criteria may be of particular interest
in the paediatric population at disease onset, when axial in-
volvement is usually absent.
Our study has several limitations. First, our data are
retrospective, and although collected from a register, not all
data were available for certain time points. Second, we used
clinicians’ opinions as a gold standard to diagnose the dis-
ease and evaluate its activity because of the lack of good
clinical criteria. Third, disease activity and treatment
Table 4 Risk factors for sacroiliitis and active disease
Sacroiliitis Active disease at the last follow up
Odds Ratio (CI 95%) p Odds Ratio (CI 95%) p
Univariate analysis
Boys 0.7 (0.3–1.6) 0.41 0.3 (0.1–0.7) 0.01
HLA-B27 0.8 (0.3–1.9) 0.67 0.9 (0.4–2.1) 0.84
Age > 12 years 1.7 (0.6–4.9) 0.31 0.4 (0.1–1.1) 0.07
Familial history of SpA 3.6 (1.6–8.2) 0.02 3.1 (1.4–7.1) 0.01
Oligo-articular involvement
at first consultation
0.5 (0.2–1.0) 0.06 0.5 (0.2–1.0) 0.06
Hip Arthritis 1.2 (0.6–2.5) 0.66 1.4 (0.7–2.9) 0.39
Enthesitis 4.7 (1.3–17.5) 0.01 1.7 (0.6–4.5) 0.32
Extra-articular involvement 1.2 (0.5–2.6) 0.69 1 (0.5–2.2) 1
Multivariable analysis
Boys 0.94 (0.4–2.3) 0.82 0.44 (0.2–1.1) 0.06
Age > 12 years 2.61 (08–8.8) 0.09 0.48 (0.1–1.6) 0.22
Familial history of SpA 3.61 (1.5–8.7) < 0.01 2.98 (1.2–7.3) 0,02
Enthesitis 4.2 (1.1–16.6) 0.04 1.55 (0.5–4.9) 0.45
Oligo-articular involvement
at first consultation
0.47 (0.2–1.2) 0.10 0.73 (0.3–1.7) 0.46
CI confidence interval
We studied the five factors (male gender, age > 12 years at disease onset, familial history of SpA, presence of enthesitis, and oligo-articular involvement at first
consultation) associated with at least one of our judgment criteria for the multivariable analysis
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response were evaluated based on the opinion of the treat-
ing physician and the Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI), Juvenile Arthritis Disease Activity
Score (JADAS), or other parameters of disease activity sta-
tus were not systematically included. Fourth, the duration
of follow-up was heterogeneous, ranging from 1.0 to
7.2 years. Fifth, only one third of patients underwent MRI.
MRI examinations in our centre were performed based on
the clinical judgement of the treating physician, mostly
when lumbosacral pain or limited spinal mobility were
present. As discussed earlier, axial disease can be clinically
silent. There is no consensus on how to consider axial dis-
ease seen only by MRI with no clinical symptoms. Sixth,
our population was followed in a tertiary centre, with
recruitment likely biased towards more severe cases.
Conclusion
We confirm that JSpA is characterised by its peripheral pat-
tern at disease onset, with peripheral arthritis and enthesi-
tis. However, axial disease developed over the next five
years in more than half our patients. MRI is clearly a valu-
able tool to assess axial involvement, but its interpretation
may be more difficult in children and require, in many
cases, an experienced radiologist. Familial history of SpA is
one of the major prognostic factors associated with both
sacroiliitis and persistence of active disease over years,
favouring the close follow-up of such patients to initiate ef-
fective and timely treatment, knowing that TNF inhibitors
have proven efficacy in JSpA/ERA patients with an inad-
equate response to NSAIDs. The current revised Edmonton
classification criteria lacked both specificity and sensitivity
to classify JSpA/ERA, which merits, among other consider-
ations, the on-going effort to improve classification criteria
of JIA. Applying the 2011 ASAS criteria for peripheral SpA
may be worth considering for JSpA, as they showed high
sensitivity to diagnose our patients both at their first assess-
ment and at the last follow-up.
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